GlassScriptPhysician profile
Alexander Ondari
NPI 1891057535
$10,773.22
in general payments reported to CMS, 2019-2025
35 companies · $3,306 in 2025
The $3,306 reported for 2025 was more than what 98% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $615 · 2022: $2,247 · 2023: $1,847 · 2024: $2,758 · 2025: $3,306.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,652 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $200 · Education: $59.35.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,651.71 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $200.00 |
| Education | $59.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,066.39 | 2021-2025 | |
| Novo Nordisk INC | $1,364.87 | 2021-2025 | Ozempic, Wegovy, Rybelsus |
| Glaxosmithkline, LLC. | $964.93 | 2021-2025 | Arexvy, Nucala, Trelegy Ellipta |
| Lilly USA, LLC | $758.30 | 2022-2025 | Zepbound, Mounjaro, Jardiance |
| Axsome Therapeutics, INC. | $679.52 | 2023-2025 | Auvelity |
| Amgen INC. | $559.24 | 2022-2025 | Evenity, Otezla, Repatha |
| Astrazeneca Pharmaceuticals LP | $551.05 | 2022-2025 | Breztri, Farxiga |
| Phathom Pharmaceuticals, INC. | $504.43 | 2024-2025 | Voquezna |
| Bayer Healthcare Pharmaceuticals INC. | $393.74 | 2023-2025 | |
| Sanofi-Aventis U.S. LLC | $390.91 | 2022-2025 | |
| Otsuka America Pharmaceutical, INC. | $385.32 | 2023-2025 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $232.89 | 2023-2025 | Austedo Xr, Austedo Xr |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $214.19 | 2025 | Caplyta |
| Eko Health, INC. | $200.00 | 2024 | |
| Vanda Pharmaceuticals INC. | $184.35 | 2025 | Fanapt |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $156.06 | 2023-2025 | |
| Janssen Pharmaceuticals, INC | $154.27 | 2022-2024 | Spravato |
| Urgo Medical North America, LLC | $140.70 | 2025 | Vashe Wound Solution 250 Ml (8.5 Fl Oz) Flip Top Cap |
| Mylan Specialty L.P. | $115.20 | 2023 | Yupelri |
| Eisai INC. | $101.12 | 2024 | |
| Biohaven Pharmaceutical Holding Company LTD. | $96.02 | 2022 | |
| Astellas Pharma US INC | $88.42 | 2024-2025 | Veozah |
| Exact Sciences Corporation | $67.35 | 2023-2025 | Cologuard Collection Kit |
| Dexcom, INC. | $55.06 | 2024-2025 | Dexcom G6 Transmitter |
| Xeris Pharmaceuticals, INC. | $46.62 | 2022-2024 | Gvoke Hypopen |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $46.33 | 2022-2024 | Xifaxan |
| Merck Sharp & Dohme LLC | $38.34 | 2023-2024 | Gardasil 9, Gardasil, M-M-R II |
| Lundbeck LLC | $37.39 | 2025 | Rexulti |
| Abbott Laboratories | $35.41 | 2024-2025 | Freestyle Libre 3 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $32.61 | 2022-2023 | Jardiance |
| Takeda Pharmaceuticals U.S.A., INC. | $29.23 | 2022-2023 | Trintellix |
| Inspire Medical Systems, INC. | $27.69 | 2025 | Inspire |
| Neurocrine Biosciences, INC. | $26.10 | 2024 | Ingrezza |
| Shield Therapeutics INC | $16.58 | 2024 | |
| Antares Pharma, INC. | $12.59 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexander Ondari listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.